Role of Hormone Receptors- Estrogen receptor, Progesterone Receptor and Human Epidermal Growth Factor Receptor 2/Neu (Her2/Neu) as a Prognostic and Therapeutic Tool in Breast Cancer
ER, PR and Her2/Neu as a Prognostic and Therapeutic Tool in Breast Cancer
Background: Breast carcinoma (BC) is the second most leading cancer which mostly occurs in younger age group. It is better to represent BC by the combined receptor expression pattern, as single receptor status alone will not help in treatment and management of tumor. This study aims to analyze the expression pattern of ER, PR and Her‑2/neu hormone receptors in BC patients for evaluating their clinicopathological correlation with other factors for BC development in the Southern Assam region of India.
Materials and Methods: 60 number of breast carcinoma cases were studied from December 2016 – November 2018. Immunohistochemical analysis of all the samples were done. Data including age, gender, tumor size, histological grade and type, lymph node status were collected from the Pathology Dept. All the data were entered and analyzed in SPSS Software. ANOVA analysis and Pearson correlation test was done for determining statistical significance.
Result: The mean age was found to be 41.33 ± 9.63. The most common type of carcinoma was found to be Invasive Breast Carcinoma (Ductal), NOS Type. Grade-II was the most prevalent type followed by Grade-III and Grade-I. PR is statistically significant with age (p=0.001) and gender (p= 0.002). ER and PR are significantly positively correlated with each other (‘r’=0.323 and p=0.012) and Her2/neu was significantly negatively correlated with ER and PR expression (‘r’= -0.333, p=0.009 and ‘r’= - 0.274, p=0.034 respectively).
Conclusion: In this present study ER/PR expressions were found to be low, while Her-2/neu over-expression was higher. So, Her-2/neu, is an important predictive and prognostic marker at a very young age.
Keywords: Her-2/neu, Prognostic marker, SPSS, Breast carcinoma, Progesterone receptor.
2. Ansari M, Mittal A, Mehta J, Jain N. Molecular Subtypes of Breast Cancer According to Immunohistochemical Expression of Hormone Receptors in A Region of North West India: A Comparative Study with Other Regions in India and Around the Globe. Int Arch BioMed Clin Res. 2019;5(1):26-30.
3. Jain SA, Aggrawal L, Ameta A, Nadkarni S, Goyal A, Ranjan D, et al. Study of ER, PR and HER-2/NEU reactivity pattern in the patient of Breast Cancer in northern part of India. IOSR-JDMS. 2014;13(2):9-19.
4. Puvitha R, Shifa S. Breast Carcinoma, Receptor Status, and Her2 neu Overexpression Revisited. Int J Sci Study. 2016;3(10):52-8.
5. AlZaman AS, Mughal SA, AlZaman YS, AlZaman ES. Correlation between hormone receptor status and age, and its prognostic implications in breast cancer patients in Bahrain. Saudi medical journal. 2016;37(1):37-42.
6. Negi M, Kumar S, Devi S, Raina SK. Profiling estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2/neu in breast carcinoma: Study of 111 consecutive cases. Journal of the Scientific Society. 2018;45(1):13.
7. Almasri NM, Al Hamad M. Immunohistochemical evaluation of human epidermal growth factor receptor 2 and estrogen and progesterone receptors in breast carcinoma in Jordan. Breast Cancer Research. 2005;7(5):1-7.
8. Ellis I, Bartlett J, Dowsett M, Humphreys S, Jasani B, Miller K, et al. Best Practice No 176: Updated recommendations for HER2 testing in the UK. Journal of clinical pathology. 2004;57(3):233-7.
9. Chand P, Garg A, Singla V, Rani N. Evaluation of immunohistochemical profile of breast cancer for prognostics and therapeutic use. Nigerian Journal of Surgery. 2018;24(2):100-6.
10. Rakha EA, Reis-Filho JS, Baehner F, Dabbs DJ, Decker T, Eusebi V, et al. Breast cancer prognostic classification in the molecular era: the role of histological grade. Breast Cancer Research. 2010;12(4):1-12.
11. Allred D, Harvey JM, Berardo M, Clark GM. Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Modern pathology: an official journal of the United States and Canadian Academy of Pathology, Inc. 1998;11(2):155-68.
12. WHO. Breast cancer2021. Available from: https://www.who.int/news-room/fact-sheets/detail/breast-cancer.
13. Foerster R, Foerster FG, Wulff V, Schubotz B, Baaske D, Wolfgarten M, et al. Matched-pair analysis of patients with female and male breast cancer: a comparative analysis. BMC cancer. 2011;11(1):1-8.
14. Siadati S, Sharbatdaran M, Nikbakhsh N, Ghaemian N. Correlation of ER, PR and HER-2/Neu with other prognostic factors in infiltrating ductal carcinoma of breast. Iranian journal of pathology. 2015;10(3):221.
15. Dixon Jr J, Page D, Anderson T, Lee D, Elton R, Stewart H, et al. Long-term survivors after breast cancer. Journal of British Surgery. 1985;72(6):445-8.
16. Fatima S, Faridi N, Gill S. Breast cancer: steroid receptors and other prognostic indicators. Journal of the College of Physicians and Surgeons--pakistan: JCPSP. 2005;15(4):230-3.
17. Ratnatunga N, Liyanapathirana L. Hormone receptor expression and Her/2neu amplification in breast carcinoma in a cohort of Sri Lankans. The Ceylon medical journal. 2007;52(4):133-6.
18. Aysola K, Desai A, Welch C, Xu J, Qin Y, Reddy V, et al. Triple negative breast cancer–an overview. Hereditary genetics: current research. 2013;2013(Suppl 2).
19. Dutta V, Chopra G, Sahai K, Nema S. Hormone receptors, Her-2/Neu and chromosomal aberrations in breast cancer. Medical Journal Armed Forces India. 2008;64(1):11-5.
20. Andres SA, Smolenkova IA, Wittliff JL. Gender-associated expression of tumor markers and a small gene set in breast carcinoma. The Breast. 2014;23(3):226-33.
21. Yadav R, Sen R, Chauhan P. ER, PR, HER2/NEU status and relation to clinicopathological factors in breast carcinoma. Int J Pharm Pharm Sci. 2016;8(4):287-90.
22. Ariga R, Zarif A, Korasick J, Reddy V, Siziopikou K, Gattuso P. Correlation of her‐2/neu gene amplification with other prognostic and predictive factors in female breast carcinoma. The breast journal. 2005;11(4):278-80
Copyright (c) 2021 Nivedita Dasgupta
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.